{
    "clinical_study": {
        "@rank": "75734", 
        "acronym": "EXPAND", 
        "arm_group": {
            "arm_group_label": "Non-valvular atrial fibrillation", 
            "description": "Patients diagnosed with non-valvular atrial fibrillation\nPatients who are treated or will be treated with rivaroxaban"
        }, 
        "brief_summary": {
            "textblock": "The efficacy and safety of a novel oral Xa inhibitor for stroke and systemic embolism,\n      namely rivaroxaban, in non-valvular atrial fibrillation patients are evaluated in Japanese\n      clinical practice."
        }, 
        "brief_title": "Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation", 
        "condition": "Non-valvular Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Embolism"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients who meet all the criteria below\n\n          -  Patients aged over 20 years\n\n          -  Patients diagnosed with non-valvular atrial fibrillation\n\n          -  Patients who are treated or will be treated with rivaroxaban\n\n          -  Patients from whom written informed consent has been obtained\n\n        Exclusion Criteria:\n\n        Patients who meet any of the criteria below\n\n          -  The following patients in whom rivaroxaban is contraindicated for use\n\n          -  Patients with a history of allergies to the ingredients contained in this drug\n\n          -  Patients having a hemorrhagic event (intracranial hemorrhage, gastrointestinal\n             hemorrhage or other clinically significant hemorrhagic events)\n\n          -  Patients having liver disease complicated with coagulation disorder or those having\n             moderate or worse liver disorder (Grade B or C in accordance with the Child-Pugh\n             classification)\n\n          -  Patients having renal failure (creatinine clearance: <15 mL/min)\n\n          -  Women who are or are likely to be pregnant\n\n          -  Patients who are treated with HIV protease inhibitors (including ritonavir,\n             atazanavir and indinavir)\n\n          -  Patients who are treated with oral or injectable formulations of azole antifungal\n             drugs (including itraconazole, voriconazole and ketoconazole (excluding fluconazole))"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Non-valvular atrial fibrillation (In the present study, non-valvular atrial fibrillation\n        refers to atrial fibrillation without a history of prosthetic valve replacement or mitral\n        valve stenosis.)"
            }
        }, 
        "enrollment": {
            "#text": "7000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147444", 
            "org_study_id": "EXPAND study", 
            "secondary_id": "UMIN000009376"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Rivaroxaban", 
            "Non-valvular atrial fibrillation", 
            "NOAC", 
            "Xa inhibitor"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "link": {
            "description": "EXPAND study home page", 
            "url": "http://cms.captool.jp/expand/"
        }, 
        "location": {
            "contact": {
                "email": "fukuda@cardio.med.tohoku.ac.jp", 
                "last_name": "Koji Fukuda, MD, PhD", 
                "phone": "+81-22-717-7153"
            }, 
            "facility": {
                "address": {
                    "city": "Sendai", 
                    "country": "Japan", 
                    "state": "Miyagi", 
                    "zip": "980-6574"
                }, 
                "name": "Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"
            }, 
            "investigator": {
                "last_name": "Hiroaki Shimokawa, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Multi-center, Prospective, Non-interventional, Observational Cohort Study to Investigate Effectiveness and Safety of Rivaroxaban on Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Japanese Clinical Practice", 
        "overall_contact": {
            "email": "fukuda@cardio.med.tohoku.ac.jp", 
            "last_name": "Koji Fukuda, M.D., Ph. D", 
            "phone": "+81-22-717-7153"
        }, 
        "overall_official": {
            "affiliation": "Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine", 
            "last_name": "Hiroaki Shimokawa, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Primary efficacy endpoint", 
                "measure": "Combinations of symptomatic stroke (ischemic or hemorrhagic) and systemic embolism", 
                "safety_issue": "Yes", 
                "time_frame": "up to March/2016"
            }, 
            {
                "description": "Primary safety endpoint", 
                "measure": "Clinically significant hemorrhagic events (massive hemorrhage in accordance with the ISTH classification)", 
                "safety_issue": "Yes", 
                "time_frame": "up to March/2016"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147444"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tohoku University", 
            "investigator_full_name": "Hiroaki Shimokawa, MD, PhD", 
            "investigator_title": "MD, PhD, Department of Cardiovascular Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Secondary efficacy endpoints", 
                "measure": "Combinations of symptomatic stroke (ischemic or hemorrhagic), systemic embolism, myocardial infarction and cardiovascular death", 
                "safety_issue": "Yes", 
                "time_frame": "up to March/2016"
            }, 
            {
                "description": "Secondary efficacy endpoints", 
                "measure": "Symptomatic ischemic stroke", 
                "safety_issue": "Yes", 
                "time_frame": "up to March/2016"
            }, 
            {
                "description": "Secondary efficacy endpoints", 
                "measure": "Symptomatic hemorrhagic stroke", 
                "safety_issue": "Yes", 
                "time_frame": "up to March/2016"
            }, 
            {
                "description": "Secondary efficacy endpoints", 
                "measure": "Systemic embolism", 
                "safety_issue": "Yes", 
                "time_frame": "up to March/2016"
            }, 
            {
                "description": "Secondary efficacy endpoints", 
                "measure": "Acute myocardial infarction/unstable angina pectoris", 
                "safety_issue": "Yes", 
                "time_frame": "up to March/2016"
            }, 
            {
                "description": "Secondary efficacy endpoints", 
                "measure": "Cardiovascular death", 
                "safety_issue": "Yes", 
                "time_frame": "up to March/2016"
            }, 
            {
                "description": "Secondary efficacy endpoints", 
                "measure": "Deep vein thrombosis/pulmonary thromboembolism", 
                "safety_issue": "Yes", 
                "time_frame": "up to March/2016"
            }, 
            {
                "description": "Secondary efficacy endpoints", 
                "measure": "Transient ischemic attack", 
                "safety_issue": "Yes", 
                "time_frame": "up to March/2016"
            }, 
            {
                "description": "Secondary efficacy endpoints", 
                "measure": "Interventional/surgical treatment", 
                "safety_issue": "Yes", 
                "time_frame": "up to March/2016"
            }, 
            {
                "description": "Secondary efficacy endpoints", 
                "measure": "All-cause death", 
                "safety_issue": "Yes", 
                "time_frame": "up to March/2016"
            }, 
            {
                "description": "Secondary safety endpoint", 
                "measure": "Clinically insignificant hemorrhagic events (hemorrhagic events other than clinically significant hemorrhagic events)", 
                "safety_issue": "Yes", 
                "time_frame": "up to March/2016"
            }
        ], 
        "source": "Tohoku University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tohoku University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "2 Years", 
        "verification_date": "May 2014"
    }
}